Skip to content
Study details
Enrolling now

Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging

Natalie Denburg
NCT IDNCT03954899ClinicalTrials.gov data as of Apr 2026
Target enrollment

230

Study length

about 6.1 years

Ages

56–85

Locations

1 site in IA

What this study is about

This trial is testing whether a treatment of 5mg melatonin improves Alzheimer's disease biomarkers and cognitive function in older adults. Participants will have blood draws to measure biomarkers, and their cognitive function will be assessed with tests. The lumbar puncture procedures for this clinical trial have been eliminated.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Melatonin
  • 2.Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

melatonin (Hormone supplement; regulates sleep-wake cycle)

Drug routes

oral (Disintegrating Oral Tablet)

Endpoints

Secondary: Sleep Efficiency

Body systems

Neurology